Phase I clinical evaluation of a neutralizing monoclonal antibody against Epidermal Growth Factor Receptor

Article

Abstract: Ior egf/r3 a neutralizing monoclonal antibody (mAb) against Epidermal Growth Factor Receptor (EGFR)

Palabras claves:

Epidermal growth factor receptor, immunotherapy, Monoclonal antibody, Phase I clinical trial, Tyrosine kinase inhibitors

Autores:

Catalaá M., Fernández E., Iznaga N., Neninger Vinageras E., Peérez R., Ramos M., Rodríguez N., Tania Crombet, Torres O.

Fuentes:

scopus